9ueo: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Co-crystal structure of Mtb CdnP with arabinose-derived 2'3'-cGAMP (AR-cGAMP) analogue== | |||
<StructureSection load='9ueo' size='340' side='right'caption='[[9ueo]], [[Resolution|resolution]] 2.60Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9ueo]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_H37Rv Mycobacterium tuberculosis H37Rv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9UEO OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9UEO FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=9UH:9-[(1~{S},6~{R},8~{R},9~{R},10~{S},15~{R},17~{R},18~{R})-8-(6-aminopurin-9-yl)-3,9,12,18-tetrakis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-2-azanyl-1~{H}-purin-6-one'>9UH</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MN:MANGANESE+(II)+ION'>MN</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9ueo FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9ueo OCA], [https://pdbe.org/9ueo PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9ueo RCSB], [https://www.ebi.ac.uk/pdbsum/9ueo PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9ueo ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/NRNA_MYCTU NRNA_MYCTU] Bifunctional enzyme which has both oligoribonuclease and pAp-phosphatase activities. Degrades RNA oligonucleotides with a length of 5 nucleotides and shorter, with a preference for 2-mers. Also degrades 24-mers. Converts 3'(2')-phosphoadenosine 5'-phosphate (PAP) to AMP.<ref>PMID:22114320</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Bacterial infection, including that ofMycobacterium tuberculosis, leads to the accumulation of the bacterial cyclic dinucleotides (CDN), c-di-AMP and c-di-GMP, and the host cGAMP synthase-catalyzed CDN, 2'3'-cGAMP in the cytosol, which activates STING-dependent type I interferon (IFN) and NF-kappaB immune responses. The mycobacterial cyclic dinucleotide phosphodiesterase (CdnP) secreted into the host macrophages blunts host immunity by directly cleaving bacterial- and host-derived CDNs. The arabinose- and xylose-modified 2'3'-cGAMP (2'3'-(A/X)cGAMP) analogues act as potent STING agonists and resist hydrolysis by the host-PDE ENPP1. Here, we report that 2'3'-(A/X)-cGAMP analogues bind to CdnP and compete with its substrate binding. Further studies revealed that these analogues inhibit the catalytic activity of CdnP. The cocrystal structure demonstrates that the arabinose-derived 2'3'-cGAMP (AR-cGAMP) analogue is trapped in an unusual U-shaped conformation in the substrate-binding pocket, away from the catalytic residue and Mn2+, which suggests that CdnP is incompetent to hydrolyze the analogue and cannot accept the other CDN substrate for hydrolysis. Given that several bacterial and viral pathogens deploy CDN phosphodiesterase enzymes to hydrolyze both host and pathogen-derived STING agonists, sugar-modified CDNs can be used to weaken bacterial and viral defenses and stimulate the STING-mediated host immunity against these pathogens. | |||
Structural and Biochemical Insights into the Arabinose and Xylose Derivatives of Cyclic-GAMP-Mediated Inhibition of Mycobacterium tuberculosis Cyclic-di-AMP Phosphodiesterase.,Hanuman DS, Neeharika S, Nitin K, Abhishek S, Sinha KM, Rajakumara E Biochemistry. 2026 Aug 4;65(15):2441-2451. doi: 10.1021/acs.biochem.6c00106. PMID:42206963<ref>PMID:42206963</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 9ueo" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Mycobacterium tuberculosis H37Rv]] | |||
[[Category: Hanuman SD]] | |||
[[Category: Nitin K]] | |||
[[Category: Rajakumara E]] | |||
Latest revision as of 08:39, 16 September 2026
Co-crystal structure of Mtb CdnP with arabinose-derived 2'3'-cGAMP (AR-cGAMP) analogue
| ||||||||||||
